N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=109 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Inflammation and Pain Following Ocular Surgery
Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) — 10; 12; 11; 27 Participants — p=0.4543
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 2 N=256 Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
Phase 2 N=60 Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of Study Eye — 6; 3 Participants
Phase 2 N=153 OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Inflammation Corneal · Pain, Postoperative
Primary: Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') — 26; 34; 10 participants
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Phase 3 N=241 OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants
Phase 3 N=438 OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants
Phase 3 N=247 Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post Ocular Surgical Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of the Study Eye — 54; 12 Participants
Phase 2 N=101 Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
Diabetic Macular Edema
Primary: Number of Participants With Intraocular Inflammation — 6; 10 Participants
Phase 3 N=514 Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 16; 46; 49 Participants
Phase 2 N=289 Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Dry Eye Disease
Primary: Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 Weeks — 78.3; 76.8; -1.1; -1.7 units on a scale
Phase 3 N=326 Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 38; 29 Participants
Phase 3 N=241 A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation Eye Pain · Postoperative Cataract
Primary: Absence of Anterior Chamber Cells at Visit 6. — 57.2; 24.0 percentage of study eyes — p=<0.0001
Phase 4 N=11 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Phase 3 N=325 Evaluation of Efficacy and Safety of SDN-037
Inflammation and Pain Associated With Ocular Surgery
Primary: Subjects With an Anterior Chamber Cell Grade of 0 at Day 15 — 96; 30 Participants — p=<.0001
Phase 4 N=46 Control of Pain in Intravitreal Injections Using Topical NSAIDs
Intravitreal Injections · IVI
Primary: McGill Pain Questionnaire (SF-MPQ) Scores at Baseline — 0.62; 0.93; 0.53 score on a scale
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=260 Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery
Inflammation and Pain Associated With Cataract Surgery
Primary: Proportion of Participants With Anterior Chamber Cell (ACC) Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT)…
Phase 4 N=16 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
Chronic Allergic Conjunctivitis
Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 19; 13 participants — p=0.0014
Phase 2 N=132 A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain After Cataract Surgery
Primary: Number of Treatment Emergent Adverse Events — 4; 7; 3; 8 Participants
Phase 3 N=369 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 49; 15 Participants
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 18; 7 participants — p=<0.0001
Phase 2 N=150 Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
Chronic Ocular Pain
Primary: Change From Baseline at Week 12 in Ocular Pain Severity Visual Analog Scale (VAS) — -23.7; -21.7; -25.3 Scores on a scale — p=0.930
Phase 2 N=100 Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Evidence of Anterior Chamber Inflammation — 1; 10; 0; 1 participants